Shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) were down 3.8% during trading on Wednesday . The stock traded as low as $16.42 and last traded at $16.56, with a volume of 56,680 shares changing hands. The stock had previously closed at $17.21.

Several analysts have recently commented on LJPC shares. SunTrust Banks Inc. started coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price target on the stock. Zacks Investment Research cut shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, August 25th. Lake Street Capital started coverage on shares of La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Jefferies Group reissued a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $38.83.

The stock’s 50-day moving average price is $17.42 and its 200 day moving average price is $17.81. The firm’s market cap is $298.64 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.09. Equities analysts predict that La Jolla Pharmaceutical Co. will post ($3.76) EPS for the current year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.